Our analysis of patients in the National Cancer Database (NCDB) shows patients with HER2‐low who received the current standard of care treatment between 2008 and 2015 had greater survival than HER2‐negative patients in multivariable analysis. This evidence concerns the gene ERBB2 and cancer.